 Bala Hota
Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcal Infections | 17 | 2021 | 176 | 3.600 |
Why?
| | Cross Infection | 21 | 2017 | 293 | 2.820 |
Why?
| | Bacteremia | 14 | 2017 | 122 | 2.310 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 11 | 2021 | 110 | 2.230 |
Why?
| | Community-Acquired Infections | 13 | 2021 | 77 | 2.030 |
Why?
| | Staphylococcus aureus | 8 | 2021 | 87 | 1.820 |
Why?
| | Methicillin Resistance | 7 | 2012 | 33 | 1.810 |
Why?
| | Hospitals | 5 | 2022 | 142 | 1.570 |
Why?
| | Catheter-Related Infections | 8 | 2015 | 26 | 1.510 |
Why?
| | Anti-Bacterial Agents | 11 | 2021 | 412 | 1.470 |
Why?
| | Infection Control | 10 | 2015 | 171 | 1.370 |
Why?
| | Intensive Care Units | 10 | 2020 | 316 | 1.300 |
Why?
| | Staphylococcal Skin Infections | 4 | 2011 | 14 | 1.190 |
Why?
| | Population Surveillance | 7 | 2010 | 127 | 1.040 |
Why?
| | Catheterization, Central Venous | 7 | 2015 | 44 | 0.940 |
Why?
| | Soft Tissue Infections | 4 | 2011 | 25 | 0.870 |
Why?
| | Benchmarking | 2 | 2019 | 34 | 0.770 |
Why?
| | Quality Indicators, Health Care | 2 | 2019 | 43 | 0.760 |
Why?
| | Electronic Health Records | 4 | 2015 | 82 | 0.750 |
Why?
| | Critical Illness | 1 | 2020 | 125 | 0.740 |
Why?
| | Quality of Health Care | 2 | 2019 | 141 | 0.730 |
Why?
| | HIV Infections | 6 | 2013 | 951 | 0.730 |
Why?
| | Hospitalization | 3 | 2020 | 359 | 0.730 |
Why?
| | Humans | 62 | 2022 | 31481 | 0.700 |
Why?
| | Pandemics | 1 | 2020 | 203 | 0.700 |
Why?
| | Coronavirus Infections | 1 | 2020 | 97 | 0.700 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 102 | 0.690 |
Why?
| | Chicago | 15 | 2020 | 955 | 0.690 |
Why?
| | United States | 17 | 2022 | 2539 | 0.680 |
Why?
| | Risk Assessment | 2 | 2020 | 806 | 0.650 |
Why?
| | Risk Factors | 13 | 2021 | 2664 | 0.590 |
Why?
| | Sepsis | 2 | 2010 | 157 | 0.590 |
Why?
| | Fluoroquinolones | 2 | 2006 | 25 | 0.590 |
Why?
| | Disease Outbreaks | 3 | 2011 | 87 | 0.580 |
Why?
| | Patient Safety | 1 | 2016 | 53 | 0.570 |
Why?
| | Middle Aged | 26 | 2022 | 11209 | 0.480 |
Why?
| | Nose | 2 | 2013 | 35 | 0.470 |
Why?
| | Female | 32 | 2022 | 18253 | 0.450 |
Why?
| | Male | 31 | 2022 | 17583 | 0.450 |
Why?
| | Algorithms | 4 | 2014 | 412 | 0.450 |
Why?
| | Drug Resistance, Bacterial | 3 | 2009 | 55 | 0.450 |
Why?
| | Prisons | 2 | 2013 | 13 | 0.450 |
Why?
| | Myositis | 4 | 2015 | 22 | 0.450 |
Why?
| | Adult | 25 | 2022 | 9779 | 0.440 |
Why?
| | Creatine Kinase | 4 | 2015 | 36 | 0.440 |
Why?
| | HIV | 1 | 2012 | 89 | 0.440 |
Why?
| | Phenotype | 5 | 2021 | 379 | 0.430 |
Why?
| | Retrospective Studies | 15 | 2020 | 3591 | 0.420 |
Why?
| | Bacteriuria | 1 | 2010 | 6 | 0.410 |
Why?
| | Knowledge Bases | 1 | 2010 | 3 | 0.400 |
Why?
| | Chlorhexidine | 4 | 2012 | 54 | 0.400 |
Why?
| | Neutropenia | 1 | 2008 | 26 | 0.360 |
Why?
| | Public Housing | 1 | 2007 | 5 | 0.330 |
Why?
| | Incidence | 7 | 2014 | 829 | 0.330 |
Why?
| | Anti-Infective Agents, Local | 4 | 2012 | 50 | 0.320 |
Why?
| | Confidentiality | 3 | 2015 | 12 | 0.320 |
Why?
| | Baths | 3 | 2012 | 26 | 0.310 |
Why?
| | Academic Medical Centers | 5 | 2015 | 158 | 0.300 |
Why?
| | Databases, Factual | 4 | 2015 | 391 | 0.300 |
Why?
| | Case-Control Studies | 4 | 2022 | 687 | 0.300 |
Why?
| | Cohort Studies | 7 | 2022 | 2014 | 0.300 |
Why?
| | Developing Countries | 1 | 2005 | 22 | 0.290 |
Why?
| | Genomics | 3 | 2021 | 46 | 0.290 |
Why?
| | Gram-Negative Aerobic Bacteria | 1 | 2005 | 4 | 0.290 |
Why?
| | Aspartate Aminotransferases | 2 | 2015 | 20 | 0.280 |
Why?
| | Alanine Transaminase | 2 | 2015 | 24 | 0.280 |
Why?
| | Fomites | 1 | 2004 | 4 | 0.280 |
Why?
| | Carrier State | 3 | 2013 | 52 | 0.280 |
Why?
| | Aged | 16 | 2022 | 10295 | 0.280 |
Why?
| | Disinfection | 1 | 2004 | 13 | 0.270 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 4 | 2015 | 39 | 0.270 |
Why?
| | Skin | 3 | 2014 | 136 | 0.260 |
Why?
| | Patient-Centered Care | 2 | 2015 | 66 | 0.260 |
Why?
| | Regression Analysis | 2 | 2015 | 319 | 0.240 |
Why?
| | Microbial Sensitivity Tests | 4 | 2021 | 117 | 0.230 |
Why?
| | Illinois | 4 | 2021 | 266 | 0.230 |
Why?
| | Prognosis | 4 | 2022 | 1028 | 0.230 |
Why?
| | Hospitals, Public | 4 | 2015 | 31 | 0.220 |
Why?
| | Clostridium Infections | 2 | 2012 | 13 | 0.220 |
Why?
| | Skin Care | 2 | 2012 | 16 | 0.220 |
Why?
| | Medical Record Linkage | 3 | 2015 | 5 | 0.220 |
Why?
| | Disease Transmission, Infectious | 1 | 2021 | 22 | 0.210 |
Why?
| | Occupational Exposure | 1 | 2021 | 27 | 0.210 |
Why?
| | Adolescent | 6 | 2022 | 2667 | 0.210 |
Why?
| | Comorbidity | 2 | 2020 | 562 | 0.210 |
Why?
| | Palliative Care | 1 | 2022 | 146 | 0.200 |
Why?
| | Enterocolitis, Pseudomembranous | 2 | 2010 | 16 | 0.200 |
Why?
| | Health Personnel | 1 | 2021 | 108 | 0.190 |
Why?
| | Multivariate Analysis | 3 | 2013 | 390 | 0.190 |
Why?
| | Decision Support Systems, Clinical | 2 | 2010 | 12 | 0.190 |
Why?
| | Sentinel Surveillance | 2 | 2009 | 8 | 0.190 |
Why?
| | Young Adult | 7 | 2022 | 2277 | 0.190 |
Why?
| | Time Factors | 6 | 2022 | 1902 | 0.180 |
Why?
| | Aged, 80 and over | 7 | 2022 | 5234 | 0.180 |
Why?
| | Adenosine A2 Receptor Agonists | 1 | 2018 | 11 | 0.180 |
Why?
| | Medical Records Systems, Computerized | 2 | 2009 | 12 | 0.170 |
Why?
| | Purines | 1 | 2018 | 35 | 0.170 |
Why?
| | Prevalence | 3 | 2020 | 544 | 0.170 |
Why?
| | Pyrazoles | 1 | 2018 | 55 | 0.170 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 63 | 0.170 |
Why?
| | Medical Audit | 1 | 2017 | 8 | 0.170 |
Why?
| | Inappropriate Prescribing | 1 | 2017 | 5 | 0.170 |
Why?
| | Hygiene | 2 | 2008 | 13 | 0.160 |
Why?
| | Dermatomyositis | 2 | 2014 | 12 | 0.160 |
Why?
| | Medical Staff, Hospital | 1 | 2017 | 21 | 0.160 |
Why?
| | Electrocardiography | 1 | 2018 | 209 | 0.160 |
Why?
| | Internal Medicine | 1 | 2017 | 34 | 0.160 |
Why?
| | Bacterial Infections | 2 | 2009 | 71 | 0.160 |
Why?
| | Heart Valves | 1 | 2016 | 6 | 0.150 |
Why?
| | Endocarditis | 1 | 2016 | 18 | 0.150 |
Why?
| | Time-to-Treatment | 1 | 2016 | 37 | 0.150 |
Why?
| | Hospital Units | 1 | 2015 | 12 | 0.150 |
Why?
| | Bacterial Load | 2 | 2013 | 13 | 0.150 |
Why?
| | Multicenter Studies as Topic | 1 | 2015 | 73 | 0.150 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2016 | 49 | 0.150 |
Why?
| | Health Information Exchange | 1 | 2015 | 4 | 0.150 |
Why?
| | Epidemiologic Methods | 1 | 2015 | 22 | 0.150 |
Why?
| | Civil Defense | 1 | 2015 | 7 | 0.150 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2015 | 7 | 0.140 |
Why?
| | Gram-Positive Bacteria | 2 | 2012 | 17 | 0.140 |
Why?
| | Prednisone | 1 | 2015 | 75 | 0.140 |
Why?
| | Software | 1 | 2015 | 74 | 0.140 |
Why?
| | Cardiac Surgical Procedures | 1 | 2016 | 98 | 0.140 |
Why?
| | Hospital Information Systems | 1 | 2014 | 5 | 0.140 |
Why?
| | Predictive Value of Tests | 3 | 2018 | 637 | 0.140 |
Why?
| | Public Health | 1 | 2015 | 66 | 0.140 |
Why?
| | Drug Resistance, Multiple, Bacterial | 2 | 2012 | 49 | 0.140 |
Why?
| | HIV-1 | 2 | 2009 | 446 | 0.140 |
Why?
| | Bacterial Proteins | 2 | 2014 | 90 | 0.140 |
Why?
| | Health Services Research | 1 | 2015 | 45 | 0.140 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 100 | 0.140 |
Why?
| | Computer Communication Networks | 1 | 2014 | 5 | 0.130 |
Why?
| | Pharynx | 1 | 2014 | 14 | 0.130 |
Why?
| | Nasal Cavity | 1 | 2014 | 36 | 0.130 |
Why?
| | Information Dissemination | 1 | 2014 | 21 | 0.130 |
Why?
| | Immunosuppressive Agents | 1 | 2015 | 163 | 0.130 |
Why?
| | Registries | 2 | 2022 | 214 | 0.130 |
Why?
| | Fructose-Bisphosphate Aldolase | 1 | 2014 | 4 | 0.130 |
Why?
| | Sensitivity and Specificity | 3 | 2011 | 580 | 0.130 |
Why?
| | International Classification of Diseases | 2 | 2011 | 25 | 0.130 |
Why?
| | Hospitals, Urban | 2 | 2015 | 37 | 0.120 |
Why?
| | Models, Statistical | 2 | 2012 | 144 | 0.120 |
Why?
| | Genotype | 2 | 2012 | 423 | 0.120 |
Why?
| | Molecular Epidemiology | 3 | 2021 | 29 | 0.120 |
Why?
| | Gram-Negative Bacteria | 2 | 2009 | 37 | 0.110 |
Why?
| | Colectomy | 1 | 2012 | 33 | 0.110 |
Why?
| | Stroke | 1 | 2016 | 367 | 0.110 |
Why?
| | Virulence | 1 | 2011 | 13 | 0.110 |
Why?
| | Reproducibility of Results | 5 | 2014 | 886 | 0.110 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2011 | 9 | 0.110 |
Why?
| | RNA, Viral | 2 | 2009 | 163 | 0.110 |
Why?
| | Klebsiella Infections | 1 | 2011 | 55 | 0.110 |
Why?
| | Clinical Coding | 1 | 2011 | 8 | 0.110 |
Why?
| | Length of Stay | 2 | 2010 | 377 | 0.110 |
Why?
| | Treatment Outcome | 5 | 2016 | 3910 | 0.110 |
Why?
| | Klebsiella pneumoniae | 1 | 2011 | 60 | 0.110 |
Why?
| | Models, Economic | 1 | 2010 | 10 | 0.110 |
Why?
| | Pulmonary Embolism | 1 | 2011 | 57 | 0.110 |
Why?
| | beta-Lactamases | 1 | 2011 | 80 | 0.100 |
Why?
| | Computer Security | 3 | 2015 | 10 | 0.100 |
Why?
| | Quality Assurance, Health Care | 1 | 2010 | 54 | 0.100 |
Why?
| | Geography | 1 | 2010 | 22 | 0.100 |
Why?
| | Spondylitis, Ankylosing | 1 | 2010 | 43 | 0.100 |
Why?
| | Cluster Analysis | 1 | 2010 | 55 | 0.100 |
Why?
| | Automation | 1 | 2010 | 12 | 0.100 |
Why?
| | Hospital Costs | 1 | 2010 | 73 | 0.100 |
Why?
| | Drug Utilization | 1 | 2009 | 27 | 0.100 |
Why?
| | Arthritis, Infectious | 1 | 2010 | 51 | 0.100 |
Why?
| | Branched DNA Signal Amplification Assay | 1 | 2009 | 1 | 0.100 |
Why?
| | Viremia | 1 | 2009 | 36 | 0.090 |
Why?
| | Drug Utilization Review | 1 | 2009 | 7 | 0.090 |
Why?
| | Disease Notification | 1 | 2008 | 4 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 191 | 0.090 |
Why?
| | Pattern Recognition, Automated | 1 | 2008 | 10 | 0.090 |
Why?
| | Artificial Intelligence | 1 | 2008 | 12 | 0.090 |
Why?
| | Health Care Costs | 1 | 2009 | 81 | 0.090 |
Why?
| | Feces | 2 | 2008 | 82 | 0.090 |
Why?
| | Data Collection | 1 | 2009 | 120 | 0.090 |
Why?
| | Gram-Positive Cocci | 1 | 2008 | 5 | 0.090 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2008 | 20 | 0.090 |
Why?
| | Viral Load | 1 | 2009 | 213 | 0.090 |
Why?
| | Phylogeny | 2 | 2021 | 67 | 0.090 |
Why?
| | Foodborne Diseases | 1 | 2008 | 3 | 0.090 |
Why?
| | Drug Administration Routes | 1 | 2008 | 12 | 0.090 |
Why?
| | Program Evaluation | 1 | 2009 | 153 | 0.090 |
Why?
| | Models, Theoretical | 1 | 2008 | 112 | 0.090 |
Why?
| | Drainage | 1 | 2008 | 55 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 257 | 0.080 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2007 | 24 | 0.080 |
Why?
| | Survival Analysis | 1 | 2008 | 379 | 0.080 |
Why?
| | Drug Resistance, Viral | 1 | 2007 | 43 | 0.080 |
Why?
| | Critical Care | 1 | 2010 | 234 | 0.080 |
Why?
| | Genome, Bacterial | 2 | 2017 | 13 | 0.080 |
Why?
| | Anti-HIV Agents | 1 | 2007 | 166 | 0.080 |
Why?
| | Sequence Analysis, DNA | 2 | 2017 | 81 | 0.080 |
Why?
| | DNA, Bacterial | 2 | 2017 | 54 | 0.070 |
Why?
| | Prospective Studies | 1 | 2011 | 1934 | 0.070 |
Why?
| | Hip Joint | 1 | 2010 | 339 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 230 | 0.070 |
Why?
| | Virus Diseases | 1 | 2004 | 15 | 0.070 |
Why?
| | Heart-Assist Devices | 1 | 2005 | 31 | 0.070 |
Why?
| | Mycoses | 1 | 2004 | 23 | 0.070 |
Why?
| | Polymyositis | 2 | 2014 | 9 | 0.070 |
Why?
| | Mass Screening | 1 | 2005 | 199 | 0.060 |
Why?
| | Poisson Distribution | 2 | 2015 | 26 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2008 | 1240 | 0.060 |
Why?
| | Therapies, Investigational | 1 | 2022 | 6 | 0.060 |
Why?
| | Prosthesis-Related Infections | 1 | 2005 | 209 | 0.060 |
Why?
| | Social Determinants of Health | 1 | 2022 | 22 | 0.060 |
Why?
| | Methicillin | 1 | 2021 | 7 | 0.060 |
Why?
| | Molecular Typing | 1 | 2021 | 9 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2015 | 265 | 0.050 |
Why?
| | Maryland | 1 | 2021 | 10 | 0.050 |
Why?
| | Georgia | 1 | 2021 | 16 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2021 | 22 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 389 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2020 | 25 | 0.050 |
Why?
| | Delivery of Health Care | 1 | 2022 | 130 | 0.050 |
Why?
| | Linear Models | 2 | 2010 | 276 | 0.050 |
Why?
| | Hospitals, Teaching | 2 | 2009 | 37 | 0.050 |
Why?
| | Residence Characteristics | 1 | 2021 | 226 | 0.050 |
Why?
| | Patient Discharge | 2 | 2010 | 163 | 0.050 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2017 | 6 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 986 | 0.040 |
Why?
| | Exercise Test | 1 | 2018 | 123 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2022 | 1452 | 0.040 |
Why?
| | Feedback | 1 | 2017 | 26 | 0.040 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2018 | 84 | 0.040 |
Why?
| | Myocardial Perfusion Imaging | 1 | 2018 | 63 | 0.040 |
Why?
| | Glasgow Outcome Scale | 1 | 2016 | 2 | 0.040 |
Why?
| | Magnetic Resonance Angiography | 1 | 2016 | 51 | 0.040 |
Why?
| | Cerebral Angiography | 1 | 2016 | 72 | 0.040 |
Why?
| | Safety-net Providers | 1 | 2015 | 9 | 0.040 |
Why?
| | Health Insurance Portability and Accountability Act | 1 | 2015 | 2 | 0.040 |
Why?
| | Urban Health Services | 1 | 2015 | 18 | 0.040 |
Why?
| | Neurologic Examination | 1 | 2016 | 160 | 0.040 |
Why?
| | Information Storage and Retrieval | 1 | 2015 | 5 | 0.040 |
Why?
| | Management Audit | 1 | 2014 | 2 | 0.030 |
Why?
| | Interinstitutional Relations | 1 | 2015 | 11 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2014 | 8 | 0.030 |
Why?
| | Genetic Markers | 1 | 2014 | 51 | 0.030 |
Why?
| | Muscle Strength | 1 | 2015 | 134 | 0.030 |
Why?
| | Renal Dialysis | 1 | 2015 | 117 | 0.030 |
Why?
| | Patient Selection | 1 | 2016 | 264 | 0.030 |
Why?
| | Information Systems | 1 | 2014 | 18 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 512 | 0.030 |
Why?
| | Substance-Related Disorders | 1 | 2015 | 115 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 2014 | 51 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 362 | 0.030 |
Why?
| | Liver Diseases | 1 | 2014 | 40 | 0.030 |
Why?
| | Quality Improvement | 1 | 2014 | 173 | 0.030 |
Why?
| | Contact Tracing | 1 | 2011 | 6 | 0.030 |
Why?
| | Multilocus Sequence Typing | 1 | 2011 | 12 | 0.030 |
Why?
| | Indiana | 1 | 2011 | 18 | 0.030 |
Why?
| | Bacterial Typing Techniques | 1 | 2011 | 12 | 0.030 |
Why?
| | Utah | 1 | 2011 | 2 | 0.030 |
Why?
| | Baltimore | 1 | 2011 | 16 | 0.030 |
Why?
| | Drug Costs | 1 | 2010 | 18 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 2010 | 39 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2010 | 52 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2010 | 132 | 0.030 |
Why?
| | Wounds and Injuries | 1 | 2011 | 58 | 0.030 |
Why?
| | Soaps | 1 | 2010 | 9 | 0.030 |
Why?
| | Biological Assay | 1 | 2010 | 9 | 0.030 |
Why?
| | Hospitals, Special | 1 | 2009 | 6 | 0.020 |
Why?
| | Organizational Policy | 1 | 2009 | 16 | 0.020 |
Why?
| | APACHE | 1 | 2009 | 32 | 0.020 |
Why?
| | Culture Media | 1 | 2009 | 44 | 0.020 |
Why?
| | Blood | 1 | 2009 | 30 | 0.020 |
Why?
| | Long-Term Care | 1 | 2009 | 58 | 0.020 |
Why?
| | Acute Disease | 1 | 2010 | 254 | 0.020 |
Why?
| | Hospitals, University | 1 | 2009 | 46 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2010 | 467 | 0.020 |
Why?
| | Escherichia coli O157 | 1 | 2008 | 2 | 0.020 |
Why?
| | Salmonella | 1 | 2008 | 5 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2009 | 77 | 0.020 |
Why?
| | Chronic Disease | 1 | 2011 | 544 | 0.020 |
Why?
| | Diarrhea | 1 | 2008 | 50 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2008 | 77 | 0.020 |
Why?
| | HIV Reverse Transcriptase | 1 | 2007 | 10 | 0.020 |
Why?
| | HIV Protease | 1 | 2007 | 9 | 0.020 |
Why?
| | CD4 Lymphocyte Count | 1 | 2007 | 161 | 0.020 |
Why?
| | Computer Simulation | 1 | 2008 | 249 | 0.020 |
Why?
| | Inpatients | 1 | 2009 | 154 | 0.020 |
Why?
| | Treatment Failure | 1 | 2007 | 187 | 0.020 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2005 | 5 | 0.020 |
Why?
| | Mutation | 1 | 2007 | 464 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2005 | 50 | 0.020 |
Why?
|
|
Hota's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|